Showing 3961-3970 of 21451 results for "".
- Large-Scale Analysis Identifies Emerging Biomarkers in Irritable Bowel Syndromehttps://reachmd.com/news/large-scale-analysis-identifies-emerging-biomarkers-in-irritable-bowel-syndrome/2486390/
- Chlorhexidine Cord Care Shows Targeted Benefit in Reducing Neonatal Infection Risk in Low-Resource Settingshttps://reachmd.com/news/chlorhexidine-cord-care-shows-targeted-benefit-in-reducing-neonatal-infection-risk-in-low-resource-settings/2486392/
- Endothelial Cell–Specific Signaling Pathway Implicated in Cardiac Fibrosis Progressionhttps://reachmd.com/news/endothelial-cellspecific-signaling-pathway-implicated-in-cardiac-fibrosis-progression/2486391/
- Revance, Teoxane Introduce RHA® Dynamic Volume for Facial Rejuvenationhttps://reachmd.com/news/revance-teoxane-introduce-rha-dynamic-volume-for-facial-rejuvenation/2486353/Revance and Teoxane have announced the availability of RHA® Dynamic Volume, formerly known as RHA® 4 Mepi, expanding the RHA® Collection with a hyaluronic acid filler designed to adapt to facial movement and support natural-looking outcomes. The product has been approved by the US Food and Drug A
- Lutikizumab Improves Clinical Response Rates in Moderate to Severe HS: Analysishttps://reachmd.com/news/lutikizumab-shows-promise-in-hs-after-anti-tnf-failure-in-phase-2-trial/2486330/In a phase 2, double-blind, placebo-controlled randomized clinical trial, lutikizumab demonstrated efficacy signals in adults with moderate to severe hidradenitis suppurativa (HS) who had previously experienced anti–tumor necrosis factor (TNF) therapy failure.
- FDA Approves ICOTYDE (Icotrokinra) for Plaque Psoriasishttps://reachmd.com/news/fda-approval-icotyde-icotrokinra-plaque-psoriasis/2486307/In a new press release, Johnson & Johnson reports that the FDA has approved
- DoriVac DNA Origami Vaccines: Preclinical Immunogenicity and Translational Noteshttps://reachmd.com/news/dorivac-dna-origami-vaccines-preclinical-immunogenicity-and-translational-notes/2486103/The DoriVac DNA origami vaccine platform is a DNA nanostructure “chassis” evaluated in preclinical mouse studies and in a microfluidic human lymph node–on-a-chip model, with both setti
- No Increase in Neovascular AMD Risk After Cataract Surgeryhttps://reachmd.com/news/no-increase-in-neovascular-amd-risk-after-cataract-surgery/2486083/New data published in JAMA Ophthalmology adds clarity to a longstanding clinical question: whether cataract
- Dietitian‑Supervised Mobile Nutrition (Nootric) in Adults with IBD: Cohort Findingshttps://reachmd.com/news/dietitiansupervised-mobile-nutrition-nootric-in-adults-with-ibd-cohort-findings/2486069/A full-length report in Nutrients describes a 24-week mobile nutrition program delivered through a dietitian-supervised Nootric® program for adu
- Topline 12‑Month BIM‑IOL Phase 1/2 Results: IOP, Vision, Safetyhttps://reachmd.com/news/topline-12month-bimiol-phase-12-results-iop-vision-safety/2486003/Sponsor-reported topline 12-month results from a multicenter, randomized Phase 1/2 trial describe the